Shiralizadeh Somaye, Azimzadeh Masoud, Keramat Fariba, Hashemi Seyyed Hamid, Majzoobi Mohammad Mehdi, Arabestani Mohammad Reza, Jalilian Farid Azizi, Taher Abbas, Khazaei Salman, Alikhani Mohammad Sina, Karami Pezhman, Rahimi Zahra, Tabar Zahra Karimi, Shakib Masoud Moghaddam, Alikhani Mohammad Yousef
Department of Microbiology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, IR Iran.
Department of Infectious Diseases, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, IR Iran.
Infect Disord Drug Targets. 2025;25(4):e18715265338445. doi: 10.2174/0118715265338445241007092436.
COVID-19 patient hospitalization, particularly in intensive care units, exposes them to bacterial and fungi co-infections, which can have very serious consequences, including increased mortality. In addition, antibiotic resistance among pathogens is a hidden threat behind COVID-19.
In the period from 2020 September to 2021 August, bacterial isolates from COVID- 19 patients admitted to the ICU of Sina Hospital in Hamadan, Iran, were collected and identified based on standard biochemical tests. COVID-19 cases were confirmed based on clinical symptoms, computed tomography, and polymerase chain reaction. Antimicrobial susceptibility tests were conducted using disc diffusion and broth microdilution methods.
In total, 207 bacterial isolates were collected, with Klebsiella pneumoniae accounting for 69 (33.33%) and Acinetobacter baumannii accounting for 59 (28.15%). The frequency and percentage of isolated bacteria were as follows: Alcaligenes species 28 (13.59%), Staphylococcus aureus 18 (8.73%), Pseudomonas aeruginosa 15 (7.28%), Escherichia coli 11 (5.33%), Stenotrophomonas maltophilia 3 (1.45%), Enterococcus species 3 (1.45%), and Serratia species 1 (0.48%). About 95.38% resistance to ceftazidime and cefotaxime and 92.31% resistance to ciprofloxacin and cefepime were found in K. pneumoniae isolates. A. baumannii isolates were 100% resistant to cefotaxime, ceftriaxone, and cefepime. About 22.22% resistance to vancomycin and 66.67% resistance to clindamycin, erythromycin, and cefoxitin were seen in S. aureus isolates.
Knowledge of bacterial co-infections and their antibiotic resistance pattern in COVID-19 patients can help in choosing effective antibiotics for the treatment and prevention of antibiotic resistance.
新型冠状病毒肺炎(COVID-19)患者住院治疗,尤其是在重症监护病房,使其面临细菌和真菌合并感染的风险,这可能会产生非常严重的后果,包括死亡率增加。此外,病原体中的抗生素耐药性是COVID-19背后的一个潜在威胁。
在2020年9月至2021年8月期间,收集了伊朗哈马丹市西纳医院重症监护病房收治的COVID-19患者的细菌分离株,并根据标准生化试验进行鉴定。COVID-19病例根据临床症状、计算机断层扫描和聚合酶链反应确诊。采用纸片扩散法和肉汤微量稀释法进行药敏试验。
共收集到207株细菌分离株,其中肺炎克雷伯菌69株(33.33%),鲍曼不动杆菌59株(28.15%)。分离出的细菌的频率和百分比如下:产碱杆菌属28株(13.59%),金黄色葡萄球菌18株(8.73%),铜绿假单胞菌15株(7.28%),大肠埃希菌11株(5.33%),嗜麦芽窄食单胞菌3株(1.45%),肠球菌属3株(1.45%),沙雷菌属1株(0.48%)。肺炎克雷伯菌分离株中,约95.38%对头孢他啶和头孢噻肟耐药,92.31%对环丙沙星和头孢吡肟耐药。鲍曼不动杆菌分离株对头孢噻肟、头孢曲松和头孢吡肟的耐药率为100%。金黄色葡萄球菌分离株中,约22.22%对万古霉素耐药,66.67%对克林霉素、红霉素和头孢西丁耐药。
了解COVID-19患者的细菌合并感染情况及其抗生素耐药模式有助于选择有效的抗生素进行治疗并预防抗生素耐药性。